Time: June 3, 2014 from 1pm to 2pm
Location: Eastern Time Zone
Website or Map: https://www.youtube.com/watch…
Event Type: webinar, ptc, translarna, ataluren
Organized By: PPMD
Latest Activity: Jun 16, 2014
Export to Outlook or iCal (.ics)
In a webinar hosted by United Parent Project Muscular Dystrophy, Robert Spiegel, MD, FACP, chief medical officer of PTC Therapeutics, presented an overview of the positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency regarding the company’s application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, and what this decision means for families living in and outside the EU.
Hi Jennifer -- the link to the recording is now available: https://www.youtube.com/watch?v=H1DeTySZu0A
Hi there, was this webinar recorded?
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service